SEHK:1093Pharmaceuticals
CSPC Pharmaceutical Group (SEHK:1093) Rallies Following Strong H1 Results As Valuation Stays In Focus
CSPC Pharmaceutical Group (SEHK:1093) is back in focus after reporting half year 2026 results, announcing a higher interim dividend and updating investors on several oncology drug milestones in China.
The recent half year 2026 earnings and oncology updates appear to have fed directly into CSPC Pharmaceutical Group’s share price momentum, with a 90 day share price return of 36.85% and a 30 day gain of 14.76% helping lift the stock to HK$9.525. The 3 year total shareholder return of 81.14%...